Sunesis Pharmaceuticals
As of the edition of 20 October 2026, Sunesis Pharmaceuticals runs 4 drugs; it is on route A at 7 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Sunesis Pharmaceuticals was merged.
- Sunesis Pharmaceuticals: merged
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 2 |
| Total | 4 |
Where it needs a new molecule
Route A at 7 targets, route B at 0 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where Sunesis Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 12 trials led
- Blood and lymph: 5 trials led
- Immune system: 3 trials led